Initial Experiences of Percutaneous Coronary Intervention Using a New-Generation Everolimus-Eluting Stent Platform

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Medical Device Technology

Background:

• The Synergy Megatron drug-eluting stent (DES) is a new platform with un reported outcomes.
• Percutaneous coronary intervention (PCI) is a common procedure for treating coronary artery disease.

Purpose of the Study:

• To evaluate the periprocedural outcomes of the Synergy Megatron DES in patients undergoing PCI.
• To assess the safety and effectiveness of this novel DES technology in a real-world setting.

Main Methods:

• A retrospective study of 139 patients undergoing PCI with the Synergy Megatron DES across two UK centers.
• Primary endpoint: cardiovascular death. Secondary endpoint: composite of non-fatal myocardial infarction, target-vessel revascularization, in-stent restenosis, and stent thrombosis.
• Post hoc analysis of intravascular ultrasound (IVUS) imaging to evaluate optimization criteria.

Main Results:

• Low rates of major adverse cardiovascular events (0.7% cardiovascular death, 0.0% secondary composite endpoint).
• No cases of longitudinal stent deformation (LSD) or acute/subacute stent thrombosis were reported.
• High rates of successful IVUS optimization achieved (74.1% in left main stem, 83.3% in right coronary artery).
• Mean minimal stent area (MSA) achieved across different coronary vessels.

Conclusions:

• The Synergy Megatron DES demonstrates very low short-term adverse events, including no LSD or stent thrombosis.
• The platform exhibits favorable overexpansion capabilities, facilitating IVUS-optimized stent parameters.
• This technology is safe and effective for treating large proximal vessels and bifurcations.